Government mulls ending cyclamate ban next year
A blue ribbon panel tentatively finds new animal studies show no cancer, birth defect, or genetic risks from cyclamate. Some doubt remains about a possible weak carcinogen link, prompting calls for more tests before FDA decision on reapproval. Abbott welcomes the possible easing of the ban as FDA weighs the panel’s conclusions.
MENTIONED IN THIS ARTICLE
Washington
J. Bernard Weinstein
Columbia University
Michael Syeda
University of Illinois
Abbott
Also Mentioned on This Page
Ing
The
Food and Drag Administration
Abbott Laboratories
FDA
Richard W. Kasperson
U.S
National Academy of Sciences
G.D. Searle & Co
DEY Brothers
Fairmount Fair
Kelley
FBI
Congress
UPI
Shoppingtown
Fairmount
Little Boys
Vocmc
Baldwinsfille Tre County Mall